Feed / DOCS

Doximity, Inc.

DOCS

Healthcare · 20.90 -1.6% today

Jodie read · what matters now

Revenue increased 13.1% versus the comparable filing period.

The story is only the start. Jodie keeps watching the filing evidence, the companies connected to DOCS, and whether its market group begins moving.

Latest storyNo Struct brief yetJodie is monitoring new filings.
Disclosed connections8 verified links5 additional receipts in Pro
Organic co-movement groupHealthcare Professional Platforms · Early FollowerDiscovered from trading behaviour, not sector labels · Open group →

Latest filing assessment · baseline

The latest filing presents a mixed picture

10-K filed 2026-05-19 against the comparable filing from 2025-05-20.

mixed
OperationsmixedEvidence score 0
liquidityconstructiveEvidence score +1
valuationmixed

What improved

  • Revenue increased 13.1% versus the comparable filing period.
  • Operating cash flow covered net income at 1.67x, improving versus the comparable period.

What weakened

  • Operating margin fell 6.6 percentage points.
  • Gross margin fell 1.1 percentage points.
  • Net margin fell 8.7 percentage points.

Filing receipts

Cost of revenue, gross profit, and gross margin Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Cost of revenue $ 70,326 $ 55,874 $ 14,452 26 % Gross profit $ 574,537 $ 514,525 $ 60,012 12 % Gross margin 89 % 90 % Cost of revenue for the fiscal year ended March 31, 2026 increased $14.5 million as compared to the fiscal year ended 2025, primarily driven by a $5.6 million increase in hosting and software costs and a $2.5 million increase related to amortization of an acquired intangible and internally developed software.

Sales and marketing Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Sales and marketing $ 163,648 $ 145,713 $ 17,935 12 % Sales and marketing expense for the fiscal year ended March 31, 2026 increased $17.9 million as compared to the fiscal year ended 2025, primarily driven by a $13.1 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, and a $6 million increase in marketing activities.

Operating Expenses Research and development Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Research and development $ 130,702 $ 93,038 $ 37,664 40 % Research and development expense for the fiscal year ended March 31, 2026 increased $37.7 million as compared to the fiscal year ended 2025, primarily driven by a $28.6 million increase in stock-based compensation as a result of new service-based as well as performance-based awards granted to new hires and existing employees, a $4.9 million increase in personnel costs due to merit increases and increase in average headcount, a $3.7 million increase in third-party contractor costs, a $1.5 million increase in...

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Who this business touches

The relationships behind DOCS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MSFTMicrosoft CorporationpartnerFull receipt with Pro →
AMWLFiling-linked namecompetitorFull receipt with Pro →
TDOCTeladoc Health, Inc.competitorFull receipt with Pro →

Filing peers

Companies whose filings use similar operating language.

You can see the shape of the network here. Pro opens 5 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →

What is moving around it

Live connections

DOCS is currently a Early Follower in the organic co-movement group Healthcare Professional Platforms. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Theme membership history

No durable theme membership has been observed for this name yet.